TCRs In Personalized Oncology With BlueSphere Bio's Keir Loiacono
Business Of Biotech
00:00
The Importance of Preclinical Data in Oncology
I don't know that our space is the same, right? Like, there are other TCR companies. I definitely think our clinical approach and our first indication is, is differentiated. We're kind of aspirational TCX 201 program and, and solid tumors could be, could be really revolutionary. It's early days, but we've had some interesting initial proof of concept. And they could be immunogenic now because we've matched them with a T cell receptor from a patient's own body. But we're on our way to doing that now.
Transcript
Play full episode
